Opinion
Civil Action 21-3500
11-23-2022
VALUE DRUG COMPANY v. TAKEDA PHARMACEUTICALS, U.S.A., INC., PAR PHARMACEUTICAL, INC., WATSON LABORATORIES, INC., TEVA PHARMACEUTICAL INDUSTRIES, LTD., TEVA PHARMACEUTICALS USA, INC., AMNEAL PHARMACEUTICALS, LLC
ORDER
KEARNEY, J.
AND NOW, this 23rd day of November 2022, upon considering Plaintiff's Motion to certify a class (ECF Doc. No. 483), Defendants' Response (ECF Doc. No. 527), Plaintiff's Reply (ECF Doc. No. 543), the parties' pre-hearing Memoranda (ECF Doc. Nos. 592, 593), following our extensive November 1, 2022 evidentiary hearing and oral argument, and for reasons in the accompanying Memorandum, it is ORDERED Plaintiff's Motion to certify a class (ECF Doc. No. 483) is DENIED without prejudice.